Roxadustat in lupus nephritis: a novel therapeutic signal for multifactorial anaemia Authors: Mario Martín-Portugués, Victor Moreno-Torres, Pedro Durán-del Campo, Lucía Martín- Tesillano, José Portoles, Ana Huerta Published: 2026 Anaemia is a frequent and clinically relevant complication of systemic lupus erythematosus (SLE), particularly in patients with lupus nephritis (LN), where systemic inflammation, impaired iron utilisation, immune-mediated mechanisms, treatment toxicity and kidney dysfunction may coexist.1 Treatment of anaemia in SLE/LN is not well established and relies on correcting reversible causes and controlling inflammatory activity. However, anaemia can persist despite control of SLE activity, creating a therapeutic challenge.2 Roxadustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) developed for anaemia associated with chronic kidney disease (CKD).2 3 Its mechanism favours erythropoiesis and improves iron availability, including a hepcidin reduction.3 These properties make roxadustat attractive in inflammatory anaemia and LN; however clinical experience remains limited. We report a patient with active LN and severe multifactorial, transfusion-requiring anaemia followed at Hospital Puerta de Hierro Majadahonda (Madrid, Spain). In this patient, roxadustat was temporally associated with a marked haematologic recovery. This case is presented as a clinical signal rather than evidence of efficacy given the concomitant use of immunosuppressive therapy and the inherent limitations of single-case observation. A man in his 50s with SLE and biopsy-proven class IV+V LN diagnosed in 2018 had previously achieved complete renal remission after treatment with cyclophosphamide, glucocorticoids and mycophenolate mofetil. After being lost to follow-up in 2023, he represented in early 2025 with a systemic flare involving renal, pulmonary and serosal manifestations. Repeat kidney biopsy in February 2025 showed active class IV LN, with an activity index of 9/24 and chronicity index of 1/12. During this flare, he developed progressive, clinically significant anaemia, with haemoglobin (Hb) decreasing from 13.6 g/dL in January 2025 to a nadir of 6.5 g/dL in May 2025, requiring red blood cell transfusion on two occasions (figure 1). The anaemia was considered multifactorial. Laboratory assessment at the Hb nadir showed low reticulocyte counts and a positive direct antiglobulin test for IgG, but no biochemical evidence of overt haemolysis, including normal lactate dehydrogenase, haptoglobin and bilirubin levels. At this time, transferrin saturation was 11%, with ferritin 1060 ng/mL, low transferrin and C reactive protein 10.0 mg/L supporting inflammation-associated anaemia with functional iron restriction. At roxadustat initiation, after partial clinical improvement and transfusion support, Hb was 9.3 g/dL and transferrin saturation had increased to 23%, while ferritin remained >1000 ng/mL. Serum creatinine was 1.31 mg/dL and estimated glomerular filtration rate was 58 mL/min/1.73 m². Although the patient had only moderate renal impairment and did not fit the profile of advanced CKD-associated anaemia, the coexistence of LN activity, inflammation and functional iron restriction provided the rationale for considering roxadustat. Hb levels evolution over time. Serial Hb measurements (g/dL) are shown over time. The vertical red dashed line indicates the date of roxadustat initiation; points represent individual laboratory values connected chronologically. Hb, haemoglobin. The LN flare was treated with three methylprednisolone pulses 500 mg, tapering prednisone from 30 mg/day, mycophenolate mofetil titrated to 2 g two times per day, rituximab 1000 mg on days 0 and 14 and monthly intravenous belimumab. Reversible causes of anaemia were assessed. No clinical or microbiological evidence of infection was identified, no antibiotics or other anti-infective treatment were required, and the elevated C reactive protein was interpreted in the context of active systemic disease with articular involvement. Despite partial Hb recovery before roxadustat initiation and a trend towards improvement in serological and renal activity markers, including anti-dsDNA antibodies, complement levels and proteinuria; anaemia remained clinically relevant. Given the persistence of inflammation-associated anaemia with functional iron restriction, roxadustat was started on 20 June 2025 at 70 mg three times weekly. No iron therapy or erythropoiesis-stimulating agents were administered. After roxadustat initiation, Hb increased progressively and sustainedly, rising from 9.3 g/dL at treatment start to 12.8 g/dL in July 2025 and 13.9 g/dL in September 2025. This response allowed gradual dose reduction, first to 50 mg three times weekly in July and then to 20 mg three times weekly in August, followed by treatment discontinuation in October 2025. No further transfusions, intravenous iron therapy, oral iron therapy or erythropoiesis-stimulating agents were required after roxadustat initiation. Renal function remained clinically stable during follow-up, and no thrombotic events, serious infections, infection-related hospitalisations or other adverse effects clearly attributable to roxadustat were observed. The interpretation of this response requires caution. Hb had already increased from its nadir of 6.5 g/dL to 9.3 g/dL before roxadustat initiation, in parallel with immunosuppressive treatment and partial control of inflammatory activity. Therefore, causality cannot be established, and the observed haematologic recovery cannot be attributed exclusively to roxadustat. Nevertheless, the case remains clinically informative. First, anaemia was severe, transfusion-requiring and persisted despite proper management of the lupus flare. Second, the postroxadustat increase in Hb was rapid and clinically meaningful, occurring without additional transfusions, iron supplementation or erythropoiesis-stimulating agents. Third, the patient showed a biochemical profile compatible with inflammation-associated anaemia and functional iron restriction, a setting in which hypoxia-inducible factor prolyl hydroxylase inhibition may be mechanistically relevant through stimulation of endogenous erythropoiesis and improved iron mobilisation.2 3 This single case suggests that roxadustat may have a potential role in selected patients with LN and severe multifactorial anaemia, particularly when inflammation-associated iron restriction and renal involvement coexist. This observation should be considered hypothesis-generating and warrants prospective evaluation. The decision to use roxadustat rather than conventional erythropoiesis-stimulating agents was based on the inflammatory context, the presence of functional iron restriction and the expectation that direct stimulation of erythropoiesis alone might be insufficient without improving iron availability.2 Roxadustat was, therefore, considered because its mechanism could theoretically address both impaired erythropoiesis and inflammation-associated iron sequestration.3 This case also illustrates the type of clinical scenario in which future studies may be most informative: patients with LN, persistent or transfusion-requiring anaemia, evidence of inflammation-associated iron restriction and no clear ongoing haemolysis, bleeding, infection or correctable nutritional deficiency. In such patients, prospective evaluation should clarify the independent contribution of roxadustat, define predictors of response, and carefully assess safety, particularly thrombotic risk. In conclusion, roxadustat was temporally associated with a marked haematologic recovery in a patient with active LN and severe multifactorial anaemia. Although causality cannot be established because of concomitant immunosuppression and spontaneous inflammatory improvement, this observation provides a clinically relevant signal supporting further study of HIF-PHI therapy in selected patients with LN-associated anaemia.